A practical reference on freeze-thaw cycling: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
| Property | Value | Notes |
|---|---|---|
| Reconstitution solvent | Sterile water or aqueous buffer | Aseptic technique recommended |
| Post-reconstitution storage | 2–8 °C short term; frozen for longer periods | Avoid repeated freeze-thaw cycles |
| Typical purity assay | Reversed-phase HPLC | Peak area used to estimate purity |
| Identity confirmation | Mass measurement | Compares observed value with expected mass |
| Main degradation routes | Hydrolysis and oxidation | Accelerated by heat and extreme pH |
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Refrigeration, continually operated, typically consumes up to 50% of the energy used by a supermarket. Doors, made of glass to allow inspection of contents, improve efficiency significantly over open display cases, which use 1.3 times the energy.
== Interactions == Monoamine oxidase inhibitors (MAOIs) taken with amphetamine may result in a hypertensive crisis if taken within two weeks after last use of an MAOI type drug. Inhibitors of enzymes that directly metabolize amphetamine (particularly CYP2D6 and FMO3) will prolong the elimination of amphetamine and increase drug effects. Serotonergic drugs (such as most antidepressants) co-administered with amphetamine increases the risk of serotonin syndrome. Stimulants and antidepressants (sedatives and depressants) may increase (decrease) the drug effects of amphetamine, and vice versa. Gastrointestinal and urinary pH affect the absorption and elimination of amphetamine, respectively. Gastrointestinal alkalinizing agents increase the absorption of amphetamine. Urinary alkalinizing agents increase the concentration of non-ionized species, decreasing urinary excretion. Proton-pump inhibitors (PPIs) modify the absorption of Adderall XR and Mydayis. Zinc supplementation may reduce the minimum effective dose of amphetamine when it is used for the treatment of ADHD. Norepinephrine reuptake inhibitors (NRIs) like atomoxetine prevent norepinephrine release induced by amphetamines and have been found to reduce the stimulant, euphoriant, and sympathomimetic effects of dextroamphetamine in humans.
=== Carbon-Carbon Composite for Hip Joint Implant === The main properties required from an artificial joint implant are long term strength and stability under cyclic load (up to seven times body weight), bio-chemical inertness, wear resistance and biological bio-compatibility. Years of clinical experience with a variety of metals and polymers fell short of achieving all the requirements. Carbon is the basic component of organic material and in certain configurations is extremely stable mechanically and chemically. In this pioneer collaboration between Rafael industry and scientists from the Technion, a carbon composite hip implant was constructed. The implant was created using carbon fibers and carbon matrix. The result achieved three dimensions stability in compression and tension. The composite hip was implanted in animal experiments at the Technion laboratory by a team of the Center for Implant Surgery. These experiments did, however, uncover the one disadvantage of carbon composite: weakness in resistance to wear in friction and cyclic motion.
Trails Through Daybreak follows Van Arkride, a mix of a detective and bounty hunter known as a Spriggan, and high schooler Agnes Claudel, who hires Van to search for eight artifacts that hold the key to solving an apocalyptic mystery. The arc is set in Calvard and is considered the start of the second half of the series. The first game, Trails Through Daybreak, was released in Japan for the PlayStation 4 in 2021. It features an action-based battle system as well as updates to the traditional turn-based system. An English version was released by NIS America in July 2024 in addition to a Nintendo Switch version. A sequel, Trails Through Daybreak II, was released in Japan for the PlayStation 4 and PlayStation 5 in September 2022 and for the Switch in July 2024. The English version released in February 2025. A third game, Trails Beyond the Horizon, was released in Japan in September 2024 and worldwide in January 2026. A sequel to Trails Beyond the Horizon is planned to end the Calvard arc.
=== Sources === Chapple, Christopher Key (1993), Nonviolence to Animals, Earth, and Self in Asian Traditions, State University of New York Press Cort, John E., ed. (1998), Open Boundaries: Jain Communities and Cultures in Indian History, SUNY Press, ISBN 0-7914-3785-X Cort, John E. (2001a), Jains in the World: Religious Values and Ideology in India, Oxford University Press, ISBN 978-0-19-513234-2 Dundas, Paul (2002) [1992], The Jains (Second ed.), London and New York: Routledge, ISBN 978-0-415-26605-5 Jaini, Padmanabh S. (1998) [1979], The Jain Path of Purification, Delhi: Motilal Banarsidass, ISBN 978-81-208-1578-0 Laidlaw, James (1995), Riches and Renunciation. Religion, economy, and society among the Jains, Oxford, ISBN 978-0-19-828031-6 Sangave, Vilas Adinath (1980), Jain Community: A Social Survey (2nd ed.), Bombay: Popular Prakashan, ISBN 978-0-317-12346-3 Shah, Umakant Premanand (1987), Jaina-rūpa-maṇḍana: Jaina iconography, Abhinav Publications, ISBN 81-7017-208-X Vallely, Anne (2002), Guardians of the Transcendent: An Ethnography of a Jain Ascetic Community, University of Toronto Press, ISBN 978-0-8020-8415-6 Wiley, Kristi L. (2009) [1949], The A to Z of Jainism, vol. 38, Scarecrow Press, ISBN 978-0-8108-6337-8
Sources: en.wikipedia.org
Louisville hotspot (23) 53°36′S 140°36′W, w= 1 az= 316° ±5° rate= 67 ±5 mm/yr Possibly related to the Ontong Java Plateau (125–120 Ma). Foundation hotspot/Ngatemato seamounts (57) 37°42′S 111°06′W, w= 1 az= 292° ±3° rate= 80 ±6 mm/yr Macdonald hotspot (24) 29°00′S 140°18′W, w= 1 az= 289° ±6° rate= 105 ±10 mm/yr North Austral/President Thiers (President Thiers Bank, 58) 25°36′S 143°18′W, w= (1.0) az= 293° ± 3° rate= 75 ±15 mm/yr Arago hotspot (Arago Seamount, 59) 23°24′S 150°42′W, w= 1 az= 296° ±4° rate= 120 ±20 mm/yr Maria/Southern Cook hotspot (Îles Maria, 60) 20°12′S 153°48′W, w= 0.8 az= 300° ±4° Samoa hotspot (35) 14°30′S 168°12′W, w= 0.8 az= 285°±5° rate= 95 ±20 mm/yr Crough hotspot (Crough Seamount, 61) 26°54′S 114°36′W, w= 0.8 az= 284° ± 2° Pitcairn hotspot (31) 25°24′S 129°18′W, w= 1 az= 293° ±3° rate= 90 ±15 mm/yr Society/Tahiti hotspot (38) 18°12′S 148°24′W, w= 0.8 az= 295°±5° rate= 109 ±10 mm/yr Marquesas hotspot (26) 10°30′S 139°00′W, w= 0.5 az= 319° ±8° rate= 93 ±7 mm/yr Caroline hotspot (4) 4°48′N 164°24′E, w= 1 az= 289° ±4° rate= 135 ±20 mm/yr Hawaii hotspot (12) 19°00′N 155°12′W, w= 1 az= 304° ±3° rate= 92 ±3 mm/yr Socorro/Revillagigedos hotspot (37) 19°00′N 111°00′W Guadalupe hotspot (11) 27°42′N 114°30′W, w= 0.8 az= 292° ±5° rate= 80 ±10 mm/yr Cobb hotspot (5) 46°00′N 130°06′W, w= 1 az= 321° ±5° rate= 43 ±3 mm/yr Bowie/Pratt-Welker hotspot (3) 53°00′N 134°48′W, w= 0.8 az= 306° ±4° rate= 40 ±20 mm/yr
=== Murine === Initial therapeutic antibodies were murine analogues (suffix -omab). These antibodies have: a short half-life in vivo (due to immune complex formation), limited penetration into tumour sites and inadequately recruit host effector functions. Chimeric and humanized antibodies have generally replaced them in therapeutic antibody applications. Understanding of proteomics has proven essential in identifying novel tumour targets. Initially, murine antibodies were obtained by hybridoma technology, for which Jerne, Köhler and Milstein received a Nobel prize. However the dissimilarity between murine and human immune systems led to the clinical failure of these antibodies, except in some specific circumstances. Major problems associated with murine antibodies included reduced stimulation of cytotoxicity and the formation of complexes after repeated administration, which resulted in mild allergic reactions and sometimes anaphylactic shock. Hybridoma technology has been replaced by recombinant DNA technology, transgenic mice and phage display.
== Peptide hormones == Kaufmann and Brown 2008 find the An. gambiae adipokinetic hormone (AKH) mobilizes carbohydrates but not lipids. Meanwhile AKH/Corazonin Peptide (ACP) does not mobilize (or inhibit mobilization) of either. Mugumbate et al., 2013 provides in solution and membrane bound structures from a nuclear magnetic resonance investigation.
== Human health == In addition to its significance for the field of evolutionary biology, de novo gene birth has implications for human health. It has been speculated that novel genes, including de novo genes, may play an outsized role in species-specific traits; however, many species-specific genes lack functional annotation. Nevertheless, there is evidence to suggest that human-specific de novo genes are involved in diseases such as cancer. NYCM, a de novo gene unique to humans and chimpanzees, regulates the pathogenesis of neuroblastomas in mouse models, and the primate-specific PART1, an lncRNA gene, has been identified as both a tumor suppressor and an oncogene in different contexts. Several other human- or primate-specific de novo genes, including PBOV1, GR6, MYEOV, and ELFN1-AS1, are also linked to cancer. Some have even suggested considering tumor-specifically expressed, evolutionary novel genes as their own class of genetic elements, noting that many such genes are under positive selection and may be neofunctionalized in the context of tumors. The specific expression of many de novo genes in the human brain also raises the intriguing possibility that de novo genes influence human cognitive traits. One such example is FLJ33706, a de novo gene that was identified in GWAS and linkage analyses for nicotine addiction and shows elevated expression in the brains of Alzheimer's patients. Further research, however, showed that FLJ33706 and other de novo gene candidates expressed in the human brain are either not translated or are diverged duplicates.
Sources: en.wikipedia.org
Standard practice is a desiccated container at −20 °C, protected from light and kept sealed between uses. Letting the vial reach room temperature before opening reduces condensation on the powder. Repeated warming and cooling of the whole container is generally avoided.
There is no broadly accepted figure for TB-500. Laboratory practice is short-term storage at 2–8 °C with longer-term aliquots frozen, and degradation is expected to increase with time and temperature. Users typically rely on their own stability checks rather than published data.
Mass measurement provides the clearest confirmation by matching an observed value to the expected one. Reversed-phase chromatography adds a purity estimate through peak integration. Combining both is standard because neither alone establishes identity and purity together.
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.